Antibody-Drug Conjugates: Technologies and Global Markets

Antibody-Drug Conjugates: Technologies and Global Markets

Report Scope

This report focuses on the global market for antibody-drug conjugates (ADCs), offering an updated review that covers their fundamental design and use across different oncology fields. In this report, market segmentation is based on payload, linker, antibody, indications, and region. The report also discusses current and developing technologies, market projections and market shares. An analysis of clinical trials, innovations, opportunities, and the latest trends in the ADC market are also discussed in the report.

The report only covers antibody-drug conjugates in which an antibody is conjugated with small-molecule cytotoxic agents (also called payload) through a linker. Alternative antibody conjugates, such as those involving antibodies linked to radioisotopes, are not covered in this report.

Report Includes

25 data tables and 45 additional tables

An updated review of the global market for antibody drug conjugates

Analyses of the global market trends, with data from 2021-2023, estimates for 2024, forecasts for 2025, and projections of compound annual growth rates (CAGRs) through 2029

Evaluation of the overall market for antibody drug conjugates, and corresponding market share analysis by payload type, linker type, antibody type, indication and region

Coverage of the latest approvals, recalls, safety alerts, and clinical trials; the technical issues related to human anti-mouse antibody (HAMA); and the factors affecting mAB drugs

Information about major and emerging technologies for the formulation of antibody drug conjugates and assessment of their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies

Discussions of the market dynamics, opportunities and challenges

Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes

Competitive intelligence, including companies’ market shares, recent M&A activity and venture funding

Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Daiichi Sankyo, Pfizer Inc., and Gilead Sciences

Companies Mentioned

ABBVIE INC.
ADC THERAPEUTICS SA
DAIICHI SANKYO CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
PFIZER INC.